CURRENT REPORT 23/2022

October 12th, 2022

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") announces that it will present the latest data on the Company's development at the upcoming AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium, to be held October 26-28, 2022 in Barcelona, Spain.

Poster presentations will concern:

- clinical data for RVU120 program in relapsed/refractory metastatic or advanced solid tumors,
- preclinical data indicating RVU120's potential to enhance therapeutic rituximab-driven NK cells-mediated cytotoxicity,
- recent results from the MTA-cooperative PRMT5 inhibitors program.

Details of the poster presentations are as follows:

Abstract Title: *"Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors"*

- Abstract Number: *67*
- Session Title: *Molecular Targeted Agents 1*
- Session date: *Wednesday, October 26, 2022*

Clinical data demonstrate in the opinion of the Company a favorable safety profile at doses of 75 mg, 100 mg, and 125 mg of RVU120 in all 9 patients enrolled to date. None of the patients experienced dose-limiting toxicity (DLT), drug-related serious adverse events (SAE), or drug-related AE of Grade 3 or higher. Disease stabilization was observed in two heavily pretreated patients, one lasting 18 weeks in gastro-esophageal junction cancer, and another, ongoing after 33 weeks in adenoid cystic carcinoma. Two patients are awaiting their first assessment. The most common reason for treatment discontinuation was progressive disease (5 patients). One patient withdrew consent, and 3 patients are ongoing. Available data, in the opinion of the Company, justifies continuation of dose escalation and collection of additional clinical data.

Abstract Title: *"RVU120, a small molecule inhibitor of CDK8/19 kinases, enhances rituximab-driven NK cells-mediated cytotoxicity both in vitro and in vivo"*

- Abstract Number: *158*
- Session Title: *Combination Therapies*
- Session date: *Thursday, October 27, 2022*

Preclinical data demonstrate that treatment with RVU120 in combination with an anti-CD20 antibody causes upregulation of LAMP1 (CD107a) surface level and increases NK cell cytotoxicity against CD20-positive positive diffuse large B-cell lymphoma (DLBCL) cell lines. The combined therapy of RVU120 with rituximab, as a model drug in-vivo was well tolerated and resulted in complete tumor regressions. NK cells isolated from animals treated by the combination confirmed the highest cytotoxic potential on cancer cells ex vivo. This study shows the potential of RVU120 in enhancing antibody-mediated antibody-dependent cellular cytotoxicity (ADCC) and reinforces in the opinion of the Company the rationale for the further development of RVU120 combination therapies in multiple settings in hematology and solid tumors.

Abstract Title: *"Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP deleted cancers"*

- Abstract Number: *45*
- Session Title: *Molecular Targeted Agents 1*
- Session date: *Wednesday, October 26, 2022*

Ryvu has identified a series of MTA-cooperative PRMT5 inhibitors with drug-like physicochemical properties that block methyltransferase activity with nanomolar IC50 values. Structurally enabled hit generation and optimization allowed for a rapid expansion and delivery of several generations of compounds with novel IP, high target engagement in cells, and selective potency in MTAP-deleted cell lines. Ryvu compounds selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, and efficacy studies with the lead compound resulted in tumor growth inhibition in MTAP -/- model, accompanied by significant inhibition of target proximal PD biomarker.

Company informs that all abstracts are available online and can be obtained from the conference site at https://event.eortc.org/ena2022/

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board